- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.10. | Elicera Therapeutics AB: Elicera Therapeutics completes Phase I part of CARMA study of ELC-301 and reports complete metabolic response in 8 of 12 patients | 267 | GlobeNewswire (Europe) | Uppsala, October 12, 2026 - Elicera Therapeutics AB (publ) today announces that the Phase I part of the CARMA study has been completed. The study is evaluating the safety and preliminary efficacy of... ► Artikel lesen | |
| 02.10. | Elicera Therapeutics to participate in upcoming investor and partnering events | 2 | Cision News | ||
| 17.09. | Elicera Therapeutics AB: Elicera Therapeutics Receives Medical Products Agency Approval to Advance CARMA Study into Phase IIa in B-cell Lymphoma | 237 | GlobeNewswire (Europe) | Uppsala, September 17, 2026 - Elicera Therapeutics AB (publ) announced today that the Swedish Medical Products Agency (Läkemedelsverket) has approved a substantial modification to the clinical trial... ► Artikel lesen | |
| 09.09. | Elicera Therapeutics AB: Elicera Therapeutics Receives Safety Committee Recommendation to Use Highest ELC-301 Dose as CARMA Moves Toward Phase IIa in B-cell Lymphoma | 234 | GlobeNewswire (Europe) | Uppsala, September 9, 2026 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on oncolytic viruses and CAR T-cell therapies... ► Artikel lesen | |
| 01.09. | Elicera Therapeutics AB: Elicera Therapeutics receives its first notice of patent allowance for ELC-201 - a Japanese patent protecting the oncolytic virus candidate against solid tumors | 218 | GlobeNewswire (Europe) | Uppsala, September 1, 2026 - Elicera Therapeutics AB (publ) ("Elicera"), a clinical stage cell and gene therapy company developing next-generation therapies based on oncolytic viruses and CAR T-cells... ► Artikel lesen | |
| 28.08. | Elicera Therapeutics AB: Elicera Therapeutics receives Notice of Allowance for U.S. patent application protecting the ELC-401 CAR T-cell candidate | 620 | GlobeNewswire (Europe) | Gothenburg, August 28, 2026 - Elicera Therapeutics AB (publ) ("Elicera"), a clinical stage cell and gene therapy company developing next-generation therapies based on oncolytic viruses and CAR T-cells... ► Artikel lesen | |
| ELICERA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 28.08. | Elicera Therapeutics AB: Elicera Therapeutics AB (publ) Interim Report 1 January - 30 June 2026 | 245 | GlobeNewswire (Europe) | Second quarter (January-March 2026)
Operating profit/loss amounted to SEK -6,305,471 (-2,892,341)
Loss for the period amounted to SEK -6,261,763 (-2,732,070)
Cash flow from operating activities... ► Artikel lesen | |
| 18.08. | Elicera Therapeutics AB: Elicera Therapeutics appoints Johan Liwing as new CEO | 552 | GlobeNewswire (Europe) | Gothenburg, August 18, 2026 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on oncolytic viruses and CAR T-cell therapies... ► Artikel lesen | |
| 11.08. | ELICERA THERAPEUTICS AB: Last patient treated in the Phase I part of the CARMA study - tumor responses in 10 of 11 patients evaluated to date | 1 | Cision News | ||
| 11.08. | Elicera Therapeutics AB: Elicera Therapeutics: Last patient treated in the Phase I part of the CARMA study - tumor responses in 10 of 11 patients evaluated to date | 301 | GlobeNewswire (Europe) | Gothenburg, August 11, 2026 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on oncolytic viruses and CAR T-cell therapies... ► Artikel lesen | |
| 24.07. | Elicera Therapeutics AB: Elicera Therapeutics consolidates its management in Uppsala - CEO transition begins and recruitment of new CEO has started | 220 | GlobeNewswire (Europe) | Gothenburg, July 24, 2026 - Elicera Therapeutics AB (publ) ("Elicera"), a clinical stage cell and gene therapy company developing next-generation therapies based on oncolytic viruses and CAR T-cells... ► Artikel lesen | |
| 18.06. | Elicera Therapeutics Receives Positive Feedback from Swedish MPA on Planned Clinical Study with ELC-401 in Grade IV Glioma | 1 | Cision News | ||
| 03.06. | ELICERA THERAPEUTICS AB: Elicera publishes annual report for 2025 | 1 | Cision News | ||
| 01.06. | Elicera Therapeutics AB: Elicera announces outcome of the rights issue | 379 | GlobeNewswire (Europe) | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, ISRAEL, CANADA, JAPAN, SOUTH AFRICA, NEW ZEALAND, RUSSIA... ► Artikel lesen | |
| 25.05. | Elicera Therapeutics AB: Elicera Therapeutics announces that the final reporting and final payment from the EIC Accelerator for the CARMA study have been approved | 525 | GlobeNewswire (Europe) | Gothenburg, May 25, 2026 - Elicera Therapeutics AB (publ) ("Elicera"), a clinical stage cell and gene therapy company developing next-generation therapies based on oncolytic viruses and CAR T-cells... ► Artikel lesen | |
| 13.05. | Elicera Therapeutics AB: Elicera Therapeutics' CSO takes temporary leave to undergo medical treatment - Di Yu appointed Acting CSO | 273 | GlobeNewswire (Europe) | Gothenburg, May 13, 2026 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on oncolytic viruses and CAR T-cell therapies... ► Artikel lesen | |
| 12.05. | XFRA CAPITAL ADJUSTMENT INFORMATION - 12.05.2026 | 1.573 | Xetra Newsboard | Das Instrument MIH0 US6067934041 MITSUBISHI HEAV.IN. ADR/1 EQUITY wird cum Kapitalmassnahme gehandelt am 12.05.2026 und ex Kapitalmassnahme am 13.05.2026 The instrument MIH0 US6067934041 MITSUBISHI... ► Artikel lesen | |
| 11.05. | Elicera Therapeutics AB: Elicera publishes information document regarding the rights issue | 425 | GlobeNewswire (Europe) | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, ISRAEL, CANADA, JAPAN, SOUTH AFRICA, NEW ZEALAND, RUSSIA... ► Artikel lesen | |
| 21.04. | Elicera Therapeutics AB: Elicera Therapeutics carries out a rights issue of approximately SEK 73 million | 353 | GlobeNewswire (Europe) | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, ISRAEL, CANADA, JAPAN, SOUTH AFRICA, NEW ZEALAND, RUSSIA... ► Artikel lesen | |
| 21.04. | Elicera Therapeutics AB: Elicera Therapeutics AB (publ) Interim Report 1 January - 31 March 2026 | 270 | GlobeNewswire (Europe) | First quarter (January-March 2026)
Operating profit/loss amounted to SEK -5,116,779 (-8,069,404).
Loss for the period amounted to SEK -5,060,060 (-8,013,462).
Cash flow from operating activities... ► Artikel lesen |
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 2,840 | -0,63 % | Der Nebenwerte-Tag: Drägerwerk verdient weniger, Douglas holt neuen Chef, dazu Hypoport und Evotec | Die kleineren Werte haben gestern mehr Schwung gezeigt als die großen. Der SDAX legte um 0,86 Prozent auf 18.224 Punkte zu. Der MDAX gewann 0,22 Prozent auf 30.088 Punkte, der TecDAX schloss 0,18 Prozent... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 730,70 | +1,83 % | Regeneron, Vidac Pharma, Krystal Biotech - Neue Wirkstoffe, gewaltige Börsenfantasie | Die Krebsmedizin steht vor einem grundlegenden Wandel. Statt ausschließlich auf klassische Chemotherapien zu setzen, greifen neue Behandlungsansätze immer gezielter in die biologischen Mechanismen von... ► Artikel lesen | |
| BRAIN BIOTECH | 2,720 | -1,09 % | BRAIN Biotech mit SONDERMELDUNG: Diese brandneue Prognose ändert einfach alles - Handeln Sie, bevor es zu spät ist! | ||
| CARDIOL THERAPEUTICS | 1,022 | -0,97 % | AstraZeneca, Cardiol Therapeutics, Kiniksa - Neue Hoffnung für Herzpatienten | Herz-Kreislauf-Erkrankungen gehören weltweit zu den größten medizinischen Herausforderungen. Während etablierte Pharmakonzerne Milliarden in neue Wirkstoffe und Künstliche Intelligenz investieren, entwickeln... ► Artikel lesen | |
| CSL | 121,98 | +0,35 % | Zesamme jeck - aber bitte Grippe-geimpft!: Grippeimpfaktion von CSL Seqirus startet erstmals in Köln | Köln (ots) - Grippeprävention dort sichtbar machen, wo viele Menschen zusammenkommen: Unter diesem Leitgedanken ist heute in Köln die Aktion "Zesamme jeck - aber bitte Grippe-geimpft!" gestartet. CSL... ► Artikel lesen | |
| BURCON NUTRASCIENCE | 0,810 | -1,82 % | Burcon NutraScience Corporation: Burcon Announces Shareholder Meeting Results and Updates Commercial Guidance | Customer demand remains strong as Company accelerates investment in manufacturing infrastructure and reliabilityVancouver, British Columbia--(Newsfile Corp. - September 24, 2026) - Burcon NutraScience... ► Artikel lesen | |
| MANNKIND | 2,814 | +3,76 % | MannKind auf der 10. Jährlich stattfindenden Chardan Healthcare Conference: Pipeline erweitert sich | ||
| OCULAR THERAPEUTIX | 5,700 | -1,72 % | H.C. Wainwright reiterates Ocular Therapeutix stock rating at buy | ||
| OXFORD NANOPORE TECHNOLOGIES | 2,606 | +0,54 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 19.10.2026 | Folgende Wertpapiere werden in den Handel an der Frankfurter Wertpapierbörse (FWB) aufgenommen.
1. US88025U1097 10X GENOMICS INC
2. NL0000852564 AALBERTS NV
3. SE0016589188 ELECTROLUX AB
4. SE0000115446... ► Artikel lesen | |
| ADAPTIMMUNE THERAPEUTICS | 0,025 | -100,00 % | Merck And ADAP Crisis Task Force Reach Agreement To Expand IDVYNSO Access | ||
| CODEXIS | 1,149 | +1,77 % | Codexis, Inc.: Codexis Enters into an Agreement with Pioneering siRNA Drug Innovator to Leverage the ECO Synthesis Manufacturing Platform to Create Stereo-defined siRNA | REDWOOD CITY, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced... ► Artikel lesen | |
| CORMEDIX | 6,662 | -4,01 % | Cormedix gets FDA priority review for Rezzayo label expansion | ||
| TELO GENOMICS | 0,024 | +2,13 % | Telo Genomics Corp.: Telo Genomics Reports Additional Clinical Research Results Comparing Blood-Based TELO-MRD with Bone-Marrow Next-Generation Flow and Next-Generation Sequencing | In matched Cleveland Clinic and Jewish General Hospital samples, blood-based TELO enumeration detected circulating plasma cells in all Adaptive clonoSEQ-positive cases reviewed and in a series of clonoSEQ-negative... ► Artikel lesen | |
| ALIGOS THERAPEUTICS | 4,510 | +0,22 % | Aligos-Aktie +37%: Ein Vorbote für mehr? | Die Aligos-Aktie ist zum Wochenauftakt förmlich explodiert und schloss unter beachtlichen Umsätzen rund +37% höher. Für Anleger unserer Community ist das ein Déjà-vu: Bereits in der Vergangenheit haben... ► Artikel lesen | |
| VTV THERAPEUTICS | 24,000 | -0,83 % | vTv Therapeutics Inc.: vTv Therapeutics Announces FDA Orphan Drug Designation for HPPD in Sickle Cell Disease | HIGH POINT, N.C., Oct. 07, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company advancing cadisegliatin, a novel oral investigational therapy for type... ► Artikel lesen |
Das Unternehmen ELICERA THERAPEUTICS AB kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,230 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ELICERA THERAPEUTICS AB finden Sie auf Wallstreet Online.